Key result
Mitral repair with pericardial augmentation yields ~87% 15-year survival in pediatric rheumatic valve disease.
Why the study?
Leaflet augmentation using glutaraldehyde-treated autologous pericardium extends mitral valve repair feasibility in tissue-deficient valves, yet long-term outcome data in exclusively paediatric rheumatic cohorts remain limited.
Does mitral valve repair with 0.6% glutaraldehyde-treated autologous pericardial leaflet augmentation provide durable long-term survival, freedom from reoperation, and freedom from valve failure in children with rheumatic mitral valve disease?
Cohort (n=66)
No
Does mitral valve repair with 0.6% glutaraldehyde-treated autologous pericardial leaflet augmentation provide durable long-term survival, freedom from reoperation, and freedom from valve failure in children with rheumatic mitral valve disease?
Mitral valve repair with glutaraldehyde-treated autologous pericardial leaflet augmentation in children with rheumatic heart disease provides 87.1% freedom from reoperation and 86.9% survival at 15 years, supporting a repair-first strategy.
Answers are grounded in this paper and cite their sources.
Long-term outcomes data on leaflet augmentation in pediatric rheumatic mitral repair are now available; hypothesis-generating and leaves open need for comparative trials.
Background Rheumatic heart disease (RHD) remains the most common cause of acquired heart disease in children in low- and middle-income countries, with the mitral valve most frequently and severely affected. Mitral valve repair is universally preferred over replacement in children to avoid prosthesis-related complications. Leaflet augmentation using glutaraldehyde-treated autologous pericardium extends repair feasibility in tissue-deficient valves, yet long-term outcome data in exclusively paediatric rheumatic cohorts remain limited. Methods Between January 1997 and December 2023, 66 consecutive children (≤ 18 years) with rheumatic mitral valve disease underwent repair with 0.6% glutaraldehyde-treated autologous pericardial leaflet augmentation at the National Heart Institute Malaysia. Primary endpoints were overall survival, freedom from reoperation and freedom from valve failure, defined as recurrent mitral regurgitation (MR) greater than moderate (> 2+) or reoperation. Kaplan–Meier analysis was used for time-to-event outcomes, with Cox regression considered exploratory because of sparse events. Results Median patient age was 12.0 years (interquartile range [IQR] 8.8–14.0); 51.5% were female. Posterior leaflet augmentation was most common (51.5%), followed by anterior (36.4%) and bi-leaflet augmentation (12.1%). Early mortality was 4.5% (*n* = 3), with six additional late deaths. Overall survival at 5, 10 and 15 years was 91.5%, 91.5% and 86.9%, respectively. Freedom from reoperation was 95.0%, 90.1% and 87.1%, and freedom from valve failure was 91.7%, 89.9% and 74.7%. Six patients underwent mitral replacement at reoperation, for stenosis in four and regurgitation in two. Median follow-up was 13.03 years (IQR 6.9–15.1). Latest echocardiographic MR grade was available for 42 patients. The exploratory hazard-ratio estimates had wide confidence intervals, and the overall Firth penalized Cox model was not significant (*p* = 0.074). Conclusions Mitral valve repair incorporating glutaraldehyde-treated autologous pericardial leaflet augmentation provided encouraging long-term freedom from reoperation in selected children with rheumatic mitral disease. This experience supports a repair-first approach when technically feasible, while recognizing the potential for recurrent regurgitation or late stenosis and the importance of longitudinal echocardiographic surveillance and rheumatic prophylaxis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a cohort in Rheumatic mitral valve disease (n=66). Mitral valve repair with 0.6% glutaraldehyde-treated autologous pericardial leaflet augmentation was evaluated on Overall survival, freedom from reoperation, and freedom from valve failure (defined as recurrent mitral regurgitation >2+ or reoperation) at 15 years. Mitral valve repair with autologous pericardial leaflet augmentation in children with rheumatic disease yielded 86.9% survival, 87.1% freedom from reoperation, and 74.7% freedom from valve failure at 15 years.
Synapse has enriched 10 related papers. Consider them for comparative context: